193 related articles for article (PubMed ID: 33187683)
21. [Hematological toxicities post-CAR-T cells: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Alsuliman T; Aubrun C; Bay JO; Beguin Y; Bigenwald C; Brissot E; Chalandon Y; Chevallier P; Pagliuca S; Magro L; Srour M
Bull Cancer; 2024 Apr; ():. PubMed ID: 38631984
[TBL] [Abstract][Full Text] [Related]
22. Considerations pertaining to cell collection and administration of industry-manufactured autologous CAR-T cells, in relation to French healthcare organization and regulations.
Chabannon C; Larghero J
Curr Res Transl Med; 2018 May; 66(2):59-61. PubMed ID: 29625832
[TBL] [Abstract][Full Text] [Related]
23. [Not Available].
Dourthe MÉ; Yakouben K; Chaillou D; Lesprit E; Dalle JH; Baruchel A
Bull Cancer; 2018 Dec; 105 Suppl 2():S147-S157. PubMed ID: 30686353
[TBL] [Abstract][Full Text] [Related]
24. Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers.
Talarmin C; Kerob S; Cartier F; Madelaine I; Mukenyi S; Schwartz E; Boissel N; Baruchel A; Thieblemont C; Parquet N; Brignier A; Lesprit E; Desproges A; Magdelonnette L; Larghero J; Mebarki M
Cytotherapy; 2020 Dec; 22(12):792-801. PubMed ID: 32732084
[TBL] [Abstract][Full Text] [Related]
25. Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy-a guidance by the GoCART Coalition Pharmacist Working Group.
Nezvalova-Henriksen K; Langebrake C; Bauters T; Moreno-Martinez ME; Ahnfelt E; Ekelund H; Domingos V; Pires V; Bonnin A; Bojanić I; Cabrerizo Y; Terwel S; Tam A
Bone Marrow Transplant; 2023 Oct; 58(10):1069-1074. PubMed ID: 37528237
[TBL] [Abstract][Full Text] [Related]
26. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
Front Immunol; 2018; 9():239. PubMed ID: 29515572
[TBL] [Abstract][Full Text] [Related]
27. [Role of advanced practice nurse within a cellular therapy unit: Guidelines from the Francophone Society of Bone Marrow Transplantation and cellular therapy (SFGM-TC)].
Jezequel T; Cheron N; Ajazi Hub R; Brouillat C; Colonnese E; Desmedt C; Evard S; Hie S; Mourrut C; Vallade D; Bouhier I; Chauvel C; Gandemer V; Mercier L; Yakoub-Agha I
Bull Cancer; 2024 Feb; 111(2S):S50-S66. PubMed ID: 36797127
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.
Thibodeaux SR; Milone MC
Clin Chem; 2019 Apr; 65(4):519-529. PubMed ID: 30593467
[TBL] [Abstract][Full Text] [Related]
29. [Not Available].
Rahal I; Cabannes-Hamy A; Boissel N
Bull Cancer; 2018 Dec; 105 Suppl 2():S158-S167. PubMed ID: 30686354
[TBL] [Abstract][Full Text] [Related]
30. [CAR-T CELLS: How does the EBMT registry monitor European activities, identify hurdles and prepare for changes in regulations].
Chabannon C; Lemaitre J; Peffault de Latour R; Neven B; Bay JO; Robin M; Kuball J; Terwel S; Mohty M; Yakoub-Agha I
Bull Cancer; 2021 Oct; 108(10S):S155-S161. PubMed ID: 34920798
[TBL] [Abstract][Full Text] [Related]
31. Advances and Challenges of CAR T Cells in Clinical Trials.
Holzinger A; Abken H
Recent Results Cancer Res; 2020; 214():93-128. PubMed ID: 31473850
[TBL] [Abstract][Full Text] [Related]
32. A guide to the collection of T-cells by apheresis for ATMP manufacturing-recommendations of the GoCART coalition apheresis working group.
Worel N; Holbro A; Vrielink H; Ootjers C; Le Poole K; Beer-Wekking I; Rintala T; Lozano M; Bonig H
Bone Marrow Transplant; 2023 Jul; 58(7):742-748. PubMed ID: 37024570
[TBL] [Abstract][Full Text] [Related]
33. [Management of cytokine release syndrome in adult and pediatric patients undergoing CAR-T cell therapy for hematological malignancies: Recommendation of the French Society of Bone Marrow and cellular Therapy (SFGM-TC)].
Yakoub-Agha I; Moreau AS; Ahmad I; Borel C; Hadhoum N; Masouridi-Levrat S; Naudin J; Nicolas-Virelizier E; Ouachée-Chardin M; Platon L; Quessar A; Roth-Guepin G; Beauvais D; Baruchel A; Cornillon J
Bull Cancer; 2019 Jan; 106(1S):S102-S109. PubMed ID: 30661749
[TBL] [Abstract][Full Text] [Related]
34. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
[TBL] [Abstract][Full Text] [Related]
35. Establishment of a cell processing laboratory to support hematopoietic stem cell transplantation and chimeric antigen receptor (CAR)-T cell therapy.
Mukherjee S; Reddy O; Panch S; Stroncek D
Transfus Apher Sci; 2021 Feb; 60(1):103066. PubMed ID: 33472742
[TBL] [Abstract][Full Text] [Related]
36. American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States.
Mahmoudjafari Z; Hawks KG; Hsieh AA; Plesca D; Gatwood KS; Culos KA
Biol Blood Marrow Transplant; 2019 Jan; 25(1):26-33. PubMed ID: 30266675
[TBL] [Abstract][Full Text] [Related]
37. Paving the Road for Chimeric Antigen Receptor T Cells: American Society for Transplantation and Cellular Therapy 80/20 Task Force Consensus on Challenges and Solutions to Improving Efficiency of Clinical Center Certification and Maintenance of Operations for Commercially Approved Immune Effector Cell Therapies.
Nikiforow S; Frigault MJ; Frey NV; Gardner RA; Komanduri KV; Perales MA; Kebriaei P; Warkentin PI; Pasquini M; Aho JL; Levine BL; Heslop HE; Hlucky TL; Habucky K; Gharibo M; Jagasia M; Locke FL
Transplant Cell Ther; 2023 Apr; 29(4):228-239. PubMed ID: 36709800
[TBL] [Abstract][Full Text] [Related]
38. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
39. A guide to manufacturing CAR T cell therapies.
Vormittag P; Gunn R; Ghorashian S; Veraitch FS
Curr Opin Biotechnol; 2018 Oct; 53():164-181. PubMed ID: 29462761
[TBL] [Abstract][Full Text] [Related]
40. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
